One of the hallmarks of cystic fibrosis is the propensity of patients to develop lung infections with Pseudomonas aeruginosa, which eventually compromises lung function. New data suggest loss of CFTR impairs lipoxin production, thus preventing resolution of lung inflammation and creating an environment susceptible to further infection.
This is a preview of subscription content, log in via an institution to check access.
References
Riordan, J.R. et al. Science 245, 1066–1073 (1989).
Gibson, R.L., Burns, J.L. & Ramsey, B.W. Am. J. Respir. Crit. Care Med. 168, 918–951 (2003).
Verkman, A.S., Song, Y. & Thiagarajah, J.R. Am. J. Physiol. Cell Physiol. 284, C2–15 (2003).
Karp, C.L. Nat. Immunol. 5, 388–392 (2004).
Serhan, C.N. Prostaglandins Other Lipid Mediat. 68–69, 433–455 (2002).
Nagase, T. et al. Biochem. Biophys. Res. Commun. 168, 485–489 (1990).
Serhan, C.N. et al. J. Exp. Med. 196, 1025–1037 (2002).
Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A. & Serhan, C.N. Science 237, 1171–1176 (1987).
Shimizu, T. & Wolfe, L.S. J. Neurochem. 55, 1–15 (1990).
Nagase, T. et al. Nat. Immunol. 1, 42–46 (2000).
Nagase, T. et al. Nat. Med. 8, 480–484 (2002).
Konstan, M.W., Byard, P.J., Hoppel, C.L. & Davis, P.B. N. Engl. J. Med. 332, 848–854 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takai, D., Nagase, T. & Shimizu, T. New therapeutic key for cystic fibrosis: a role for lipoxins. Nat Immunol 5, 357–358 (2004). https://doi.org/10.1038/ni0404-357
Issue Date:
DOI: https://doi.org/10.1038/ni0404-357
- Springer Nature America, Inc.
This article is cited by
-
Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease
Clinical Reviews in Allergy & Immunology (2008)